Terumo To Accelerate Product Development And Expand Home Healthcare Market In Japan
This article was originally published in PharmAsia News
Japanese medical device maker Terumo plans to develop new products and strengthen its home oxygen therapeutic business. The company will accelerate commercializing compact and efficient oxygen condensing devices used in home intravenous therapies. In Japan, Terumo accounts for 10 percent of the home oxygen therapeutic market and 90 percent of the home intravenous therapy market. The company is focusing in Tokyo, central Japan and the Kansai area. Patients in other areas are covered through agents or local dealers. Terumo aims to increase annual sales from an estimated ¥4.3 billion in 2009 to ¥18 billion within ten years. (Click here for more - Japanese language
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.